Initially, KRAS mutations were targeted using PJ collected from patients with PDAC/IPMN for PJC and could complement the less-sensitive cytology evaluation and help in follow-up [113–115]. This evidence concerns the gene KRAS and pancreatic intraductal papillary-mucinous neoplasm.